For nearly three decades, prostate-specific antigen (PSA) has been used for prostate cancer screening, resulting in a significant increase in the number of detected cases of prostate cancer, with a shift toward detecting the cancer at earlier stages2,3. This evidence concerns the gene PROS1 and prostate carcinoma.